8. Shrewd Trader Jun 14, 2017 3:14:14 PM IST Reply Eris Lifesciences Limited IPO
What is strange is the view- As per FY 16 data this issue is overpriced but if we annualize the FY 17 data this issue seems a value buy- all thanks to reduced FY 17 expenses. In EV terms too issue looks Expensive. SPT has clearly considered FY 17 Annu. figures to roll out his verdict and thus ignored the older data. Geogit has cautioned retail investors to stay away from this issue.
I was applied 1lot eris through pnb asba, then withdraw my application succesfully. But till now my lien amount was not released. What can I do? Please suggest me any one. Thank you
you write only today..because keep watching from morning ..in a week time you forgot ERIS ...come and see here after 3 quarters you will realise....go and write about Listing gain in CDSL board
Lets go down and accumulation starts...one year time frame or atleast see 2 quarters....dont come and write anything before...just beacus you dont get the listing gains
face value only 1 Rs, more downside can be expected by the END of the day. Better to watch on sidelines than making any fresh entry. Generic drug rule also not in favour of this stock.